Harrow, Inc.
Harrow, Inc. (Nasdaq: HROW) develops, markets and sells ophthalmic medicines and provides customized compounded medications for eye-care needs. Its branded portfolio includes therapies for dry eye disease, ocular anesthesia, cataracts, inflammation, infections, retinal diseases and other eye conditions, sold primarily… From the company’s description.
Over the twelve months to Jun 30, 2026, Harrow, Inc. reported revenue of $275.59M, up 21.1% from a year earlier, and a net loss of $37.23M. Its operating margin was −1.0%, and operations generated $6.25M in cash. In fiscal 2025, it reported revenue of $272.30M, up 36.4% from fiscal 2024, and a net loss of $5.14M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Harrow, Inc. does
In the company’s own words
Harrow, Inc. (Nasdaq: HROW) develops, markets and sells ophthalmic medicines and provides customized compounded medications for eye-care needs. Its branded portfolio includes therapies for dry eye disease, ocular anesthesia, cataracts, inflammation, infections, retinal diseases and other eye conditions, sold primarily to U.S. eyecare professionals and healthcare institutions. Products include VEVYE, IHEEZO, TRIESENCE, ILEVRO and NATACYN; the portfolio also includes biosimilars BYOOVIZ and OPUVIZ, with commercial launches planned for 2026 and 2027, respectively. Harrow’s ImprimisRx business compounds formulations for ophthalmologists, optometrists and their patients when commercially available products may not meet clinical needs, using a 503A pharmacy and a 503B outsourcing facility in New Jersey. Its pipeline includes ophthalmic treatments and MELT-300, an orally disintegrating sedation candidate. Harrow owns the MELT-300 program following its 2025 acquisition of the remaining interests in Melt Pharmaceuticals. ImprimisRx serves more than 10,000 U.S. eyecare prescribers and institutions, and its formulary includes over 30 compounded formulations.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NASHVILLE, TN
- Fiscal year end
- December
- CIK
- 1360214
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Harrow, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Harrow, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Harrow, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Harrow, Inc.’s debt, $98.79M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 8.63%, maturing 2030 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Harrow, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Harrow, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Harrow, Inc.'s last four quarterly filings that the numbers alone won't show?”